CUE

Cue Biopharma Inc

18.66

Nov 11 • 3:59 PM ET -0.10 (-0.53%)

18.66

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: EVMN JSPR CLDX UPB NKTR SPRY CABA HOWL REGN NVS

| Held by: VTI VXF IWC AVSC AVTM

Scroll to Statements

Index	-
Market Cap	135.55M
Enterprise Value	126.97M
Income	-164.11M
Sales	37.65M
Book/sh	0.44
Cash/sh	2.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	29
IPO	Jan 02, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	3.60
P/B	42.24
P/C	7.79
P/FCF	-
EV/EBITDA	-
EV/Sales	3.37
Quick Ratio	1.25
Current Ratio	1.25
Debt/Eq	3.81
LT Debt/Eq	3.11
Option/Short	No / Yes

EPS (ttm)	-27.00
EPS next Y	-7.44
EPS next Q	-2.24
EPS this Y	-197.74%
EPS next Y	70.24%
EPS next 5Y	7.19%
EPS past 3/5Y	42.63% 29.04%
Sales past 3/5Y	180.45% 54.16%
EPS Y/Y TTM	-63.33%
Sales Y/Y TTM	354.37%
EPS Q/Q	-805.64%
Sales Q/Q	166.66%
Earnings	Aug 14 AMC
EPS/Sales Surpr.	-1328.40% 162.57%

Insider Own	19.77%
Insider Trans	-5.70%
Inst Own	23.36%
Inst Trans	20.66%
ROA	-459.60%
ROE	-1603.48%
ROIC	-1729.46%
Gross Margin	99.31%
Oper. Margin	-261.97%
Profit Margin	-435.83%
SMA20	-1.70%
SMA50	-23.39%
SMA200	-13.25%
Trades

Shs Outstand	7.26M
Shs Float	5.83M
Short Float	14.80%
Short Ratio	3.32
Short Interest	0.86M
52W High	45.50 -58.99%
52W Low	4.97 275.38%
Volatility	12.95% 11.93%
ATR (14)	2.40
RSI (14)	43.41
Beta	2.82
Rel Volume	0.47
Avg Volume	259.55K
Volume	122,989

Perf Week	-5.95%
Perf Month	-4.65%
Perf Quarter	-39.96%
Perf Half Y	-36.68%
Perf YTD	103.67%
Perf Year	-8.93%
Perf 3Y	-73.07%
Perf 5Y	-95.88%
Perf 10Y	-
Recom	1.00
Target Price	88.00
Prev Close	18.76
Price	18.66
Change %	-0.53%

Consensus

Strong Buy

Avg. Price Target

$88.00

Implied Upside

+371.6%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 18, 2026	Initiated	RB. Riley Securities	Buy	$83	+344.8%
Mar 13, 2024	Initiated	JJefferies	Buy	$6	-67.8%
Jun 26, 2023	Resumed	OOppenheimer	Outperform	$10	-46.4%
Nov 21, 2022	Initiated	PPiper Sandler	Overweight	$7	-62.5%
Jan 13, 2022	Initiated	HH.C. Wainwright	Buy	$20	+7.2%
Jan 03, 2022	Initiated	CCraig Hallum	Buy	$28	+50.1%
Nov 24, 2020	Initiated	BBerenberg	Buy	$30	+60.8%
Apr 09, 2020	Initiated	SStifel	Buy	$21	+12.5%
Jan 28, 2020	Initiated	BBTIG Research	Buy	$26	+39.3%
Jan 22, 2020	Initiated	JJMP Securities	Mkt Outperform	$22	+17.9%

Sep-22-26 10:17AM	An orexin drugs proof-of-concept in ADHD; Cues unwarranted share slide (BioPharma Dive) +9.30%
Sep-21-26 06:55AM	Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results (InvestorsHub) -23.70%
Sep-20-26 06:00AM	Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria (GlobeNewswire)
Aug-14-26 04:05PM	Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) +10.04% -19.18%
Aug-03-26 08:30AM	Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission (GlobeNewswire)
08:30AM	Loading…
Jul-13-26 08:30AM	Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development (GlobeNewswire) -15.93%
Jul-09-26 09:40PM	Cue Biopharma Announces $50.0 Million Private Placement (GlobeNewswire)
Jun-02-26 04:05PM	Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution (GlobeNewswire) +18.93% -5.97%
May-21-26 04:05PM	Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +6.82%
May-14-26 04:07PM	Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments (GlobeNewswire) -14.05% -9.16%
May-07-26 07:07PM	Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.15%
Apr-30-26 04:25PM	Cue Biopharma Announces $30 Million Private Placement (GlobeNewswire) +13.38% +106.38%
04:15PM	Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody (GlobeNewswire)
04:05PM	Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company (GlobeNewswire)
Apr-22-26 08:37AM	Cue Biopharma Announces 1-for-30 Reverse Stock Split (GlobeNewswire) -13.42%
10:30AM	Loading…
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press) +65.37%
08:00AM	Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 (GlobeNewswire)
Apr-10-26 10:30AM	BC-Most Active Stocks (Associated Press) +71.36%
Apr-08-26 08:00AM	Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement (GlobeNewswire) +45.48%
Apr-07-26 10:30AM	BC-Most Active Stocks (Associated Press) +6.33%
Mar-27-26 04:05PM	Cue Biopharma Announces CEO Transition (GlobeNewswire) -5.60%
Mar-26-26 08:00AM	Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 (GlobeNewswire) -5.03%
Mar-16-26 04:05PM	Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire) +9.80% -12.84%
Mar-09-26 08:00AM	Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 (GlobeNewswire)
Feb-17-26 08:00AM	Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.06%
Feb-12-26 08:00AM	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer (GlobeNewswire) -6.75%
Dec-19-25 08:00AM	Cue Biopharma Announces Pricing of $10 Million Public Offering (GlobeNewswire) -21.58%
Dec-18-25 04:02PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire) -14.50%
Nov-12-25 05:25PM	Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.19%
04:05PM	Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
05:55PM	Loading…
Nov-07-25 05:55PM	CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-06-25 06:00PM	Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates (Zacks)
08:00AM	Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors (GlobeNewswire)
Nov-05-25 06:35PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-30-25 08:20AM	Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Sep-29-25 09:00AM	Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates (GlobeNewswire)
Aug-21-25 08:00AM	Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-13-25 08:00AM	Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme (GlobeNewswire)
Aug-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-08-25 07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 06:00PM	scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-16-25 08:00AM	Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer (GlobeNewswire) +22.29%
Jul-01-25 04:05PM	Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies (GlobeNewswire)
Jun-24-25 04:48PM	Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease (GlobeNewswire) +10.43% +8.67%
May-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-08-25 08:00AM	Cue Biopharma to Host Virtual Investor Event on May 15, 2025 (GlobeNewswire)
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-05-25 10:00AM	Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire)
May-02-25 10:00AM	Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline (Zacks)
May-01-25 10:01AM	Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-30-25 09:30AM	Boehringer, Oxford University and Cumulus to explore brain activity in BPD (Pharmaceutical Technology)
Apr-16-25 04:58AM	Boehringer and Cue Biopharma to develop autoimmune therapies (Pharmaceutical Technology)
Apr-15-25 06:12PM	Cue Biopharma, Inc. (CUE) Business Update Call (Transcript) (Seeking Alpha)
02:00AM	Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases (GlobeNewswire)
Apr-14-25 10:23PM	Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering (GlobeNewswire)
05:05PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire)
05:02PM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
05:00PM	Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases (GlobeNewswire)
Mar-31-25 05:15PM	Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -17.67%
04:20PM	Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire)
Mar-28-25 09:15AM	ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.00%
Nov-29-24 04:30PM	Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 08:00AM	Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-14-24 05:25PM	Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -17.00%
04:05PM	Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
08:00AM	Cue Biopharma Announces Strategic Organizational Transition (GlobeNewswire)
Nov-12-24 08:00AM	Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference (GlobeNewswire) -9.09%
Nov-08-24 01:30PM	Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting (GlobeNewswire)
Oct-04-24 09:00AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +41.60%
Sep-26-24 11:26PM	Cue Biopharma Announces Pricing of $12.0 Million Public Offering (GlobeNewswire) +49.61%
11:10PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire)
Sep-09-24 08:00AM	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer (GlobeNewswire)
Sep-03-24 08:00AM	Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference (GlobeNewswire) -8.96%
Aug-20-24 09:36AM	Q2 2024 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) +13.68%
Aug-19-24 04:05PM	Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +11.93%
Aug-14-24 07:45PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-13-24 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Jul-26-24 10:13AM	Cue Biopharma downsizes to focus on autoimmune pipeline (Pharmaceutical Technology)
Jul-25-24 04:05PM	Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements (GlobeNewswire)
Jun-04-24 08:00AM	Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting (GlobeNewswire) -5.45%
Jun-03-24 08:00AM	Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024 (GlobeNewswire)
May-30-24 03:30PM	Medical Moonshots: 3 Biotech Stocks Set to Skyrocket (InvestorPlace)
May-09-24 11:54PM	CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -9.14%
04:05PM	Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-08-24 08:00AM	Cue Biopharma to Present at the 20th Annual PEGS Boston Summit (GlobeNewswire) -12.39%
May-07-24 08:00AM	Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-25-24 09:35AM	Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks (Zacks)
Apr-24-24 10:01AM	Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -5.33%
Apr-15-24 09:55AM	Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now (Zacks) -8.86%
Apr-09-24 07:36AM	Q4 2023 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) -6.86%
03:02AM	Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ... (GuruFocus.com)
Apr-08-24 04:05PM	Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights (GlobeNewswire) +10.27%
Apr-02-24 01:53PM	CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Feb-29-24 10:00AM	Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium (GlobeNewswire)
Feb-06-24 08:00AM	Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.46%
Dec-14-23 07:04AM	CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023 (InvestorPlace)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ray Sumita	Chief Legal Compliance Officer	Oct 12 '26	Sale	28.05	1,844	51,724	116,701	Oct 14 09:39 PM
Meluzio Michael Vincent	VP, Prin. Accounting Officer	Oct 12 '26	Sale	28.05	1,144	32,089	47,817	Oct 14 09:38 PM
Lin Shao-Lee	Chief Executive Officer	Oct 12 '26	Sale	27.55	11,087	305,490	694,908	Oct 14 09:37 PM
Shao-Lee Lin	Officer	Oct 12 '26	Proposed Sale	27.55	11,087	305,490		Oct 13 08:56 PM
Sumita Ray	Officer	Oct 12 '26	Proposed Sale	28.05	1,844	51,724		Oct 13 08:53 PM
Ray Sumita	Chief Legal Compliance Officer	Aug 13 '26	Option Exercise	0.00	18,196	0	127,374	Aug 17 06:22 PM
Ray Sumita	Chief Legal Compliance Officer	Aug 13 '26	Sale	30.09	8,829	265,628	118,545	Aug 17 06:22 PM
Meluzio Michael Vincent	VP, Prin. Accounting Officer	Aug 13 '26	Option Exercise	0.00	13,647	0	54,589	Aug 17 06:19 PM
Meluzio Michael Vincent	VP, Prin. Accounting Officer	Aug 13 '26	Sale	30.09	5,628	169,324	48,961	Aug 17 06:19 PM
Lin Shao-Lee	Chief Executive Officer	Aug 12 '26	Option Exercise	0.00	109,179	0	764,253	Aug 14 08:46 PM
Lin Shao-Lee	Chief Executive Officer	Aug 12 '26	Sale	27.10	40,000	1,083,989	724,253	Aug 14 08:46 PM
Lin Shao-Lee	Chief Executive Officer	Aug 13 '26	Sale	28.62	18,258	522,573	705,995	Aug 14 08:46 PM
Shao-Lee Lin	Officer	Aug 12 '26	Proposed Sale	27.01	40,000	1,080,400		Aug 14 08:45 PM
Sumita Ray	Officer	Aug 13 '26	Proposed Sale	30.14	8,829	266,106		Aug 13 09:50 PM
Sarraf Pasha	Director	Dec 30 '25	Buy	0.31	323,857	99,747	323,857	Jan 02 04:00 PM
MATTEO GIACOMO LEVISETTI	Officer	Dec 29 '25	Proposed Sale	0.26	7,230	1,907		Dec 29 04:00 PM

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Principal Accounting Officer & Chief Business OfficerMs. Lucinda Warren

MSEMr. Colin G. Sandercock J.D.

Ph.D.Dr. Shao-Lee Lin M.D.

Ph.D.Dr. Ronald D. Seidel III

Co-FounderDr. Rodolfo Jose Chaparro Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

CUE

Cue Biopharma Inc

Upgrade your Finviz experience

All the Features.
Half the Price.